Communication

News

AGS Therapeutics to collaborate with Sanofi on intestinal mucosal vaccination by oral administration using AGS’ MEV technology as a vaccinal delivery system

10 October 2024
News

Evry, France, October 10, 2024 – AGS Therapeutics, a preclinical-stage biotech company pioneering
microalgae extracellular vesicles (MEVs) as a new, universal delivery system, today announced
that it has entered into an agreement with Sanofi, in the context of the 2024 iDEA-TECH Awards.
AGS will thus embark on a twelve-month collaborative research project together with scientific
experts at Sanofi’s Vaccine business unit to further validate AGS’ MEVs against undisclosed targets,
in general, and as a vaccinal delivery system for oral-intestinal mucosal vaccination, in particular.
This collaborative work leverages the unique capabilities of AGS’ MEVs and the strength of AGS’
intellectual property in the vaccination and immunomodulation fields (cf. PR from October 1, 2024,
on the publication of the relevant patent). To know more